STOCKS TELEGRAPH

Author: ST Staff

  • Pulmatrix Inc. (PULM) stock fell in the current market trading session; here’s why

    Pulmatrix Inc. (PULM) shares were falling -17.05% to trade at $1.07 in the current market at the last check. PULM stock closed the previous session at $1.29. The PULM stock volume remained 3.44 million shares, which was higher than the average daily volume of 3.02 million shares within the past 50 days. PULM shares have fallen by -3.01% over the last 12 months

    What is recently happening in PulmatrixInc?

    Today, the biopharmaceutical company, Pulmatrix, Inc. (PULM) has announced that it will withdraw the portfolio of narrow spectrum kinase inhibitor (NSKI) from Johsnon& Johnson. This news came in due to Johnson & Johnson’s enterprise innovation’s decision to forfeit Pulmatrix’s license, development, and commercialization agreement.

    The NSKI portfolio also contained PUR1800, the development of which the company has stated it will seek to continue. The development will be done with ongoing clinical and toxicology studies which will allow the programs in acute exacerbations in COPD (AECOPD) and other chronic airway diseases to be supported.

    Pulamtrix’s continuance of PUR1800 program

    PULM stock has created a new updated strategy for the PUR1800 program;

    Initially, the current progress is that 28-day toxicology studies have been completed that showed PUR1800 to have improved and stable chemical and physical structure with a reduced potential of drug’s accumulation in the lung. Study has also demonstrated dose proportional systemic exposure and potential for it to be stable for long-term dosing as compared to RV162 (predecessor drug).

    Phase 1b clinical study of PUR1800 in AECOPD is ongoing along with dosing. The objective includes finding the safety, tolerability, and exploratory biomarkers for assisting in the demonstration of target engagement and anti-inflammatory effect. The topline data is expected to be gathered in the 4th quarter of 2021.

    PUR1800’s phase 2b test for proof-of-concept efficacy is to be initiated for the treatment of AECOP in this year. Pulmatrix also has an ongoing toxicology study for long term which will be data from 6-9 months. This will help explore the chronic dosing paradigms and potential where non-steroidal and inti-inflammatory treatment can be of benefit.

    Why PUR1800 program is good for PULM stock

    The CEO of PULM stock, Ted Raad stated that the phase 2b study of AECOPD has a peak-net revenue potential in US of total $2.5 billion. He furthers comments that the combination of iSPERSE along with progress in PUR1800 has an opportunity to address new paradigms of treating steroid resistant and infection driven inflammations related to lung-conditions.

    Insight on the product offerings and background of PULM stock

    PULM stock is about a company based on biopharmaceuticals that focuses on the development of treatments and therapies using innovative and unique approach to its design and creation. The company specifically focuses on addressing pulmonary and non-pulmonary diseases. PULM stock does this through inhaled-specific therapies using their own flagship technology – iSPERSETM.

    iSPERSETM is the proprietary and patented engineered dry powder delivery platform on which all of the candidates for Pulmatrix are based upon. This dry powder platform is specifically chosen for its improved and efficient therapeutic delivery to the lungs as well as reduced side-effects and maximizing local concentrations. All of this improves the overall pulmonary and non-pulmonary health and treatment of the patients.

    Another of the company’s proprietary product pipeline includes treatment of lung-related serious diseases as well as neurologic disorders. This includes bronchopulmonary aspergillosis (ABPA), lung cancers and migraines.

  • Oncolytics Biotech Inc. (ONCY) stock Rises today: Why is it so?

    Oncolytics Biotech Inc. (ONCY) stock Rises today: Why is it so?

    Shares of Oncolytics Biotech Inc. (ONCY) were down today amid the announcement of the preclinical data on Pelareorep-based combination therapies at the annual meeting held in the American Association for Cancer Research(AACR). ONCY stock price saw a downtrend of 5.71% to drop at $3.78 a share at the time of this writing. ONCY stock was red in the last trading session and was down by 13.58% at closing. Let’s deep dive to explore more of it.

    What’s happening?

    The data presented by ONCY stock in the AACR annual meeting represents the ability of the pelareorep to synergize with multiple anti-cancer agents. poly (ADP)-ribose polymerase 1 (PARP-1) inhibitor talazoparib and the Cyclin-dependent kinase (CDK) 4/6 inhibitor Palbociclib showed the top results, and both of these were approved by the U.S.A Food and Drug Administration for the cure of breast cancer.

    The data of the study of AWARE-1 window-of-opportunity breast cancer met the trials primary endpoint according to the representation given by ONCY at the meeting. The data is represented in the electronic poster at AARC which include twenty HR+/HER2- early-stage breast cancer patients in AWARE-1’s first two cohorts. The treatment was done through pelareorep and letrozole without cohort 1 or with cohort 2 before the surgery. The main purpose of AWARE-1 is to evaluate the cohort 1 and cohort 2.

    The CEO of Oncolytics Biotech said that the current data of the clinical and preclinical study support pelareorep that has much high potential to increase the effectiveness of various immunotherapies as well as wide range of immunotherapeutic agents.

    Aleix Prat, Translational Principal Investigator of AWARE-1, said that the AWARE-1 data confirms the fact that the pelareorep interact with the checkpoint inhibitors in order to train the immune system in battle against cancer.

    About ONCY stock:

    Oncolytics Biotech Inc. (ONCY) is a biopharmaceutical company focused on the discovery and development of pharmaceutical products to treat cancer in patients. Pelareorep is the lead product of Oncology which is used to treat solid tumors and hematological malignancies. ONCY founded in 1998 and its headquarters is in Calgary, Canada.

    Conclusion:

    Things are gloomy for ONCY stock as far as market sentiment is concerned. ONCY stock happened to be green at one point today but then again became red. Hence individuals eyeing Oncology stock need to do a lot of research before taking any decision.

  • Why is Kaixin Auto Holdings (KXIN) stock Gaining today?

    Why is Kaixin Auto Holdings (KXIN) stock Gaining today?

    Kaixin Auto Holdings (KXIN) announced the cooperation agreement between Haitaoche Limited, an online retailer platform for imported vehicles,  and Jingdong Century Trade Limited, China’s largest retailer platform,  after which KXIN stock price pushed by 8.93% to reach $3.05 a share as of this writing. It seems that today’s announcement has made the stock green as it went down by 3.78% at the previous closing. Let’s try to figure out more from current happenings.

    Cooperation agreement between Haitaoche and Jingdong:

    According to the cooperation agreement, Haitaoche would get access to the eCommerce auto sales market which is growing at a rapid pace. Haitaoche will expand its business in terms of both revenue and growth via leveraging its resources and expertise in the sales of consumer vehicles as well as providing the whole range of value-added services. Both companies are optimistic to generate  RMB 2 billion revenue through Haitaoche’s consumer vehicle sale on the Jingdong platform. This means that the volume of the sales will increase at least 50 %annually during the next three years. Total sales are expected to be RMB 9.5 billion under this cooperation agreement.

    Back on December 31, 2020, Kaixin stock signed the definitive purchase agreement with Haitaoche Limited according to which KXIN stock will obtain 100% Haitaoche’s share capital from Haitaoche’s shareholders.

    Recent Event of Kaixin stock:

    Back in the previous week on April 06, 2021, KXIN stock announced the definitive securities purchase agreement with Renren Inc according to which, purchaser put the investment of $6.0 million in the newly designated convertible preferred shares of the company. The preferred shares would be converted to the ordinary shares at the conversion price of $3.00 per share subjective to the customary adjustments in connection with the Purchase agreement.

    Conclusion:

    KXIN stock happened to be green after facing the bearish sentiment at the previous trading session as investors are responding to the cooperation agreement news announced by the Kaixin stock. Investors having long-term prospects usually don’t consider much the lows and highs of the stock rather they eye on the company’s fundamentals, balance sheet, and future developments. Hence it is better to analyze the KXIN balance sheet as well as future growth prospects before adding this stock to the portfolio.

  • Tesla Inc. (TSLA)’s Leading Position at Risk?

    What is Tesla?

    Tesla is an American electric automobile and green energy firm, functioning privately, with Elon Musk as its Chief Executive Officer, Zachary Kikhorn as its Chief Financial Officer and Robyn Denholm as the company’s Chairman. The company’s major products include solar panels, solar roof tiles, battery energy storage, and electric cars, for which it is famously known for.

    Investors Interested in Safer Options

    In February 2021, CNBC reported Tesla’s biggest drop in stock prices since September 2020, when it closed down 8.55%. Ever since 2021 began, Tesla has been having a hard time. As of April 12, TSLA  stock share is at $677.02 which is more than 23% lower than the stock’s peak price. It seems that is the stockholders continue to sell their stocks and opt for safer choices, Tesla could drop even further.

    Emerging Competition

    Another reason for the stock prices going down is the rise of potential competitors. At the moment, Tesla enjoys the privilege of being the number one electric car manufacturer, but with time, more and more players are entering the arena. In September 2020, Tesla had 18% of the global market share in electric cars, followed by Volkswagen at 6%. Chinese companies are now emerging as key actors. For example, firms like NIO and XPeng are being replaced by Tesla in China, which is the biggest market for electric cars. Similarly, other companies like BYD, and Ford are threatening Tesla’s position as the market leader, hence affecting its stock prices negatively.

    Is it wise to invest in Tesla?

    The question remains: should one invest in Tesla right now? Even though the company is going through a rough patch, it is still leading the electric vehicles industry. Elon Musk, the company’s CEO is known for his innovative ideas. Tesla is also working closely with Apple in order to complete and implement a clean and green battery storage projects. If we look in the long run, these projects will give an upper hand to Tesla. However, it must be noted that Tesla has already used these positives and valued their stocks at a sky-high price. This means that the company is left behind with very less wiggle room and it cannot afford to take any wrong decisions at this point. Having said this, the higher the risk there is, higher will be the profit you generate!

  • BriaCell Therapeutics Corp. (BCTX) stock increased over 10% in Pre-Market: Let’s find out why

    BriaCell Therapeutics Corp. (BCTX) stock increased over 10% in Pre-Market: Let’s find out why

    Share of BriaCell Therapeutics Corp. (BCTX) surpassed 10% in the pre-market trading session today. BCTX stock saw a push of 13.82% to reach $5.93 a share at the time of this writing. It seems that BCTX stock continued the rising momentum as it went up by 18.95% at the previous closing. But what made the stock high in the stock market? Let’s try to find it.

    What’s happening?

    There is no particular news by the  BriaCell stock today to justify the bull. No signs of analyst upgrades or upswing BCTX per share targeted price to explain the rally. However, BrialCell announced on March 30 about its selection to present the analysis result of its research related to breast cancer at the American Association for Cancer Research (AACR) Annual Meeting 2021. The dates announced for the meeting were April 10 to 15 and May 17 – 21.

    The first week of the meeting is ongoing and there is a strong possibility that investors are responding to the results announced by the company in the meeting. The analysis result to be announced in the meeting would be related to the clinical analysis and pathological data of BriaCell’s lead product, Bria-IMT for treatment of advanced breast cancer as well as Phase I/IIa clinical study of Bria-IMTin combination with immune checkpoint inhibitors which include pembrolizumab, a Merck’s product, and INCMGA00012, a product of Incyte Corporation.

    BCTX stock previous news:

    On February 26, 2021, BCTX stock closed the underwritten public offering of its common units. 4,852,353 common units were offered in that offering with US$4.25 per unit purchase price. Each unit consisted of one share of common stock of BCTX along with one warrant to the purchase of one share of BCTX’s common stock. 1,030,000 pre-funded units were offered at the public price of  US$4.24 each and consisted of a pre-funded purchase warrant of common stock and one Warrant. The US$25 million gross proceeds resulted from this offering without deducting the underwriting discounts and other related expenses.

    Conclusion:

    BCTX stock price is continuously rising despite no recent news by BriaCell Therapeutics. It would be interesting to see how long this trend would continue in the future. The final results of research related to breast cancer would greatly influence the future of the BriaCell stock.

  • Obalon Therapeutics Inc. (OBLN) stock soared in the recent premarket trading session. here’s why

    Obalon Therapeutics Inc. (OBLN) shares rose by 11.42% to trade at $3.22 in premarket at the time of writing. OBLN’s stock lost -2.36% on Friday’s session as it closed at $2.89. The volume traded is 0.54 million shares, which was lower than the average daily volume of 1.08 million shares within the past 50 days. OBLN shares have risen by 319.27% over the last 12 months, and they have moved down by -2.69% in the past week.

    What is recently happening in the company?

    On 20th March 2021, reminded OBLN shareholders that it has an ongoing investigation into Obalon Therapeutics Inc. and thus encourage them to discuss this investigation with the firm to know their rights. Here’s why the investigation is taking place.

    On 20th January 2021, Obalon Therapeutics Inc. announced an agreement to merge with another weight loss company by the name of ReShapeLifesciences Inc. The news caused OBLN stock to soar by six-hold in volume trading and rose by 503.4% in price.

    This news had a positive effect on the stock and operational performance however the news also came with its fair share of investigations asking about the nature and details of this agreement. On 21st January 2021, a law-firm called WeissLaw LLP announced that it was starting an investigation in the possible breaches of fiduciary duty and other violations of law by Board of Directors in Obalon Therapeutics Inc.

    The possible breaches include if whether the company acted in the best interest of Obalon’s public shareholders when deciding for this proposed merger and if so does the merger agreement sufficiently compensates the shareholders of Obalon.

    ReShapeLifesciences Inc. will acquire Obalon. The all-stock transaction is pertinent to OBLN stock to change its name to ReShapeLifeSciences, Inc. and the ticker will be changed “RSLS” traded under NASDAQ. The merger acquisition after completion will let ReShape stakeholders to own 51% approximately while Obalon stockholders will own 49% of the combined stock.

    Obalon’s weight-loss medical device- Oballon Balloon System

    The core medical product of the company is a device by the name of Obalon Balloon System. This system is designed specifically to provide treatment in the form of weight loss for patients having obesity problem. The functioning of the Obalon Balloon System is such that it is administered through a capsule that can be orally taken. The capsule contains an inflatable balloon that is attached to a microcatheter. Obalon Therapeutics Inc. has its own microcatheter by the name of Obalon Touch Inflation Dispenser. The inflation is done semi-automatically with a hand-held inflation device that inflates the balloon as it is placed. The microcatheter traces and displays the location on the balloon to guide its inflation which is done through a canister of mixed gases.

    This process is a reversible and repeatable weight loss solution which does not require any invasive surgery or alteration in the anatomy of the patient. It is usually recommended by physicians.

    Obalon’s background

    Obalon Therapeutics, Inc. is a technology company which is specifically based on a vertically integrated medical technology structure. It was founded in 2008 and the HQ is established in Carlsbad, California. The Company focuses on the development and commercialization of medical devices that are differentiated for treating people with weight problems and obesity. The company had three retail treatment centers in California, as of 27th February 2020.

  • Fortess Biotech Inc. (FBIO) soared in the after-market trading session; here’s why

    Fortess Biotech Inc. (FBIO) soared in the after-market trading session; here’s why

    Fortress Biotech Inc. (FBIO) stock was rising by 8.82% to trade at the price of %5.92 in the aftermarket, at the time of writing. FBIO’s stock closed in Friday’s session by trading at $5.44 which is an 11.48% gain. The stock volume traded is 22 million shares which is higher than the average daily volume of 1.63 million for the past 50 days. FBIO shares had moved by 41.30% in the past week and in the past three months It gained 56.77%. Furthermore, for the past 6 months and 12 months, it has added 26.22% and 186.32% respectively.

    Fortress’s operational activities in April

    Fortress Biotech Inc. and specifically its partner Journey Medical Corporation’s stock have been performing fundamentally well recently and they have been very active operation activity-wise in the start of April.

    Fortress BioTech Inc. (NASDAQ: FBIO) announced on 7th April 2021 that it will participate on the 20th Annual Needham Virtual Healthcare Conference which will take place from today 12th to 15th of April. Fortress’s Chief Executive Officer, President, and Chairman, LindsayA. Rosenwald, M.D, will participate in the meeting as well as one-on-one meetings during the conference. The company’s presentation will be available on their website link (click here)

    On 5th April, the partner company of Fortress BiotTech, Inc. named Journey Medical Corporation announced that it has entered into an agreement on Line of Credit with East West Bank for the amount of $7.5 million. This line of credit will be entered and received into receivables and cash of the company with an interest rate greater of 4.25%.

    On 1sth April, the Journey Medical Corporation had announced an agreement to acquire Qbrexza (glycopyrronium) which is the treatment of primary axillary hypherhidrosis in adults and pediatric populations, as well as self-administered patients. This issue is pertinent to the characterization of excessive sweating on the hand’s palms, soles of feet, armpit, groin area and under the breasts. Qbrexza is approved by the Food and Drug Administration and has generated $24 million net sales in the USA, 2020. Journey Medical Corporation will close the transaction early in the second quarter of this year.

    Fortress Biotech Inc.’s candidate programs and acquisitions

    Fortress Biotech Inc. is a biopharmaceutical company that focuses mainly on acquisition, development and commercialization of high-potential marketed and development-stage drugs and drug candidates. The product candidates that Fortress currently has in its pipeline include the bio-pharmaceutical areas of oncology, gene therapy and rare diseases. For these areas of expertise, 7 of the candidates have been marketed as pharmaceutically prescribed products and over 25 programs in development progress. Together these developed and developing products in the pipeline cover 6 large market areas which show that the FBIO stock is highly diversified.

    The business model

    To maintain these diversified and expansionary operational activities, FBIO has a team model structured around world-class business development team that has the expertise of the biopharmaceutical industry. This is highly crucial for the company to expand the company into new avenues of biopharmaceutical product opportunities.

    FBIO stock, as an opportunity to expand biopharmaceutical products, has extended partnerships with several world-renowned and famous biopharmaceutical companies as well as institutions which include AstraZeneca, Fred Hutchinson Cancer Research Center, Nationwide Children’s Hospital as well as many others.

  • Qualigen Therapeutics, Inc. (QLGN) fell in the after-hours trading session; here’s why

    Qualigen Therapeutics, Inc. (QLGN) fell in the after-hours trading session; here’s why

    QLGN stock had plunged -18.08% to trade at $2.13 in the after-market at the time of writing. QLGN stock closed the Friday trading session at $2.60 which was 0.76% lower. The volume of trade was 0.48 million shares which was lower than the average daily volume of 1.49 million for the past 50 days.

    What is recent activity of QLGN stock

    The biotech company has been operationally active in the month of March through engaging in conferences, making administrative changes and advances, as well as the acquisition of new biotech technologies.

    On March 9th, the QLGN stock announced that it has a newly gained Chief Financial Officer for Qualigen’s corporate headquarters in Carlsbad, California. The company promoted ShishirSinha to CFO who has been valuable to the company for the past 15 years.

    The company also took part in the presentation at the Oppenheimer 31st Annual Healthcare Conference from 16-18th March. The conference would provide investors a broad spectrum of all the public and private healthcare companies in the health industries of various specialties and niches.

    On 1st March, QLGN announced that it was looking into an entered agreement known as Material Evaluation and Option Agreement with the University College of London. The agreement purpose is to seek options of advancing the commercial expansion of drug candidate ALAN AS1411-GNP. The agreement is known as Material Evaluation and Option Agreement.

    Core operational focus of QLGN stock

    Currently, Qualigen Therapeutics is focusing on maintaining and expanding its core FastPack® system that has been approved by the Food and Drug Administration. The system is also ISO-certified and sold across the globe through a commercial partnership with Sekisui Diagnostics, LLC. FastPack® system has helped physicians, medical clinics, and hospitals in providing efficiency in diagnostic procedures. The system comes in the form of diagnostic instruments and test kits. The FastPack System specifically focuses on rapid point-of-care diagnostic tests for cancer, as well as men’s health, hormone functions, and vitamin D status. Since the pandemic has struck, FastPack® also provides quick and efficient diagnostics of anti –bodies against SARS-CoV-2.

    Background into the Company

    Qualigen therapeutics is a biotechnology company based in Carlsbad, California. It aims to focus on the design and production of new therapies that are novel treatment, innovative in nature.  These treatments are specifically being clinically experimented and bio-engineered to focus on cancer and infectious diseases.

    The Qualigen Therapeutic has cancer therapeutics as candidates that are still going through the development stage. The pipeline of QLGN stock includes three candidates which are ALAN (AS1411-GNP), RAS-F and STARSTM.

    ALAN (AS1411-GNP) is a cancer drug candidate that has its DNA coated in gold nanoparticles. The uniqueness of this drug is that in can target numerous cancer types and does it with minimal side effects. The base of the drug is the nucleolin-targeting DNA aptamer. The foundational DNA aptamer is also an experimental candidate that is used for the treatment of viral-based infections as well as COVID-19.

    STARS is also a DNA/RNA based treatment which a device that is also in the candidate stage. The purpose of this device is to remove the targeted tumor and viral compounds in the blood circulation.

    RAS-F belongs to the family of RAS oncongene protein-protein interaction inhibitor small molecules. This family of RAS molecules is used for the prevention of mutated RAS genes’ proteins from binding in their effector proteins. Prevention of this binding allows for the stoppage of tumor growth process. This is effective especially in the lung cancer, pancreatic and colorectal cancers.

  • What’s going on with Immutep Limited (IMMP) stock today?

    What’s going on with Immutep Limited (IMMP) stock today?

    Shares of the Immutep Limited (IMMP) stock were declining today after recording the gain of 11.32% at the previous closing. IMMP stock price saw a downtrend of 5.76% to drop at $3.37 a share as of this writing. We find no news today to link with IMMP stock however it achieved FDA approval for one of its pipeline candidates on April 8, 2021, after which IMMP stock jumped as much as 14.8% during the last trade. Let’s deep dive to explore more of it.

    What’s happening?

    Immutep Limited (IMMP) is a biotech company working on the research and development of various pharmaceutical products for the cure of cancer and various autoimmune diseases. There is no activity by the IMMP stock today to justify the falling stock price but this downtrend might be due to profit takers stepped in.

    Yesterday, On April 8, 2021, IMMP received the FDA approval for its lead product candidate eftilagimod alpha, a soluble LAG-3 protein used to treat recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). This fast-track designation approval has been granted after the reporting of phase 2 clinical data by the Immutep in combination with Keytruda, a cancer drug of Merck, to address the unmet medical needs related to HNSCC.

    IMMP entered the second collaboration with Merck on March 16, 2021, in order to evaluate the eftilagimod alpha in combination with Keytruda, a Merck’s cancer drug, in phase 2 clinical trial.

    Prior to FDA approval, on April 7, 2021, IMMP announced that it had been granted patent number EP3317301 by the European patent office. Novartis AG is the co-owner of the patent and the expiry date of  Immutep S.A.S is 28 July 2036.

    Conclusion:

    IMMP stock was down today after enjoying the bullish sentiment at the previous trading session. Currently, we find no products of Immutep in the market and most of its pipeline candidates are in the early stages of development. Immutep partnerships with big companies like Pfizer, Merck, and others are a good sign of its reputation. In a nutshell, investors need to do fundamental as well as technical analysis before adding this stock to their portfolio.

  • SPAR Group Inc. (SGRP) stock plunged in the pre-market trading session: here’s why

    SPAR Group Inc. (SGRP) stock plunged in the pre-market trading session: here’s why

    Recently in the premarket trading session, SGRP stock plunged by -11.95% to the price $1.4. SGRP stock decreased by -1.24% as it closed at $1.59 for the last trading session. Shares of SPAR Group Inc. had oscillated between $1.50 and $1.63 throughout the day.

    The volume of shares that remained was 0.17 million which is less than the average daily volume of 0.38 million for the past 50 days. In the past 1 year, the company’s stock rose by triple digit percentage of 104.45% and gained 101.78% in the last 6 months.  The average 3 month volume is 343.68k; over the last three months SGRP stock gained 38.26%. Furthermore, the stock has a current market of $33.60 million and its outstanding shares stood at 21.11 million.

    The recent negative pattern of trading of SGRP stock in the pre-market came along with no recent news this month. However at the end of the month of March, the SGRP reported the financial results of the Q4 and full-year 2020.

    Insights on the SPAR group background

    SPAR Group is a merchandising company as well as a marketing company that is globally renowned. The company provides a vast range of product offerings and services. Its clients are usually retailers, manufacturers and distributors across the globe. The company has under-its-belt, 40 years of experience. The number of merchandising specialists that the company has around the world is 20,000. While the average footfall of the store visits consist of 200,000+ daily visits.

    Fourth-Quarter and Full Year Financial Report 2020

    The company announced the full financial year report on 31st March 2020.

    Here are what the highlights about the Fourth quarter say.

    • The net revenue was $59.4 million for Q4 2020, while it was $61.1 million in the Q4 2019;
    • Domestic net revenue had increased by 11.9% while international net revenue had decreased
    • Gross profit was $11.5 million for Q4 2020 while it was $12 million in the Q4 2019
    • Operating income improved 148% to $2.9 million for Q4 2020 while it was $1.2 million for Q4 2019
    • The Earnings Per Share had increased by 425%

    Here are the Full Year Results of the SGRP stock

    • Consolidated net revenue was $230.5 million for Q4 2020 compared to $252.9 million for Q4 2019
    • Gross Profit decreased to $45.2 million for Q4 2020 compared to $49.3 million for Q4 2019
    • Operating income decreased to $9.7 million for Q4 2020 compared to $10.2 million for Q4 2019
    • Net EPS increased by $0.04 per share to $0.16 per share for Q4 2020.

    SPAR Group Outlook

    SPAR Group has not released or issued any revenue or earnings guidance with the financial year 2020 report. This non-issue of guidance is now common in companies because of the Coivd-19 pandemic’s volatility and unpredictability which can also have an effect on the company’s economic and macroeconomics factors. SGRP plans to focus towards growth and stability for its operational and stock performance.